

SUBJECT INDEX TO VOLUME 5

ACTH biosynthesis	259	Bile flow	153
transcriptional regulation of	259	cholestasis associated alteration to	153
Acute biliary pancreatitis	193	pharmacological intervention to modify	153
pathogenesis of	193	therapeutic interventions to modify	158
prevention of	193	Bile salt	131
primary prevention of	196	transport of	131
secondary prevention of	196	Biliary efflux	155
treatment of	193	Biliary lipids	132, 185, 203
Adhesion molecules	404	drugs affecting secretion of	185
as targets	404	effects of leptin on	203
Amino acid transporter ATB ⁰⁺	357	Biliary lithogenesis	171
as delivery system for drugs	357	Biliary proteins	181
as delivery system for prodrugs	360	Biliary water	193
as drug delivery system	361	pharmacological manipulation of	193, 196
comparison with PEPT1	361	Biological sealant (tissucol)	339
drawbacks of	362	clinical pictures of	341
molecular nature of	358	economic aspects of	342
substrate specificity of	358	with fibrin-glue (T-I)	339
tissue distribution pattern of	361	Bone loss	353
tissue expression of	358	therapeutic targets for	353
transport drugs <i>via</i>	358	Brain ischemia	270
transport mechanism of	358	models of	270
transport of carnitine <i>via</i>	359	pancaspase inhibitors in	279
transport of nitric oxide synthase		pro-apoptotic caspases in	279
inhibitors <i>via</i>	358	Breast cancer	379
transport of D-serine <i>via</i>	360	acquired endocrine resistance in	388
Antigen specific immune response	397	<i>de novo</i> endocrine resistance	387
Apoptosis	12	development of breast tissue in	379
prevention of	12	endocrine therapy for	385
Aquaporins	138	endocrine resistance in	387
canalicular secretion of water mediated by	138	estrogen synthesis in	380
Aquaporin water channels	137	gene-based approaches for	389
cell membrane water permeability of	137	molecular basis of	379
Aryl hydrocarbon receptor	2	targeting ER for	389
Aspartate	360	targeting ERE for	390
Atherosclerosis	174	therapeutic strategies for	379, 385
Beta-oxidation	27	use of antiestrogens	386
of mitochondria fatty acid	27	use of aromatase inhibitors	385
Bile	137, 174	use of GnRH antagonist	385
cholesterol secretion in	177	Breast tissue	379
effects of	174	Canalicular glutathione efflux	153
flow of	137	contribution of	153
generation of	137	to bile formation	153
modulation of cholesterol crystallization in	180	Cancer	333, 365, 414
precipitation/crystallization of cholesterol in	178	anti-cancer chemotherapy for	414
solubilization/transport in	177	autoimmunity in	417
Bile acid	209, 214, 289	combination immunotherapies for	417
feedback regulation of	289	cruciferous vegetables in	333
metabolism of	210	dendritic cell immunotherapy for	416
kinetics of	214	effects of vitamins	335
regulation of	289	garlic in	333
synthesis of	209, 289	grains in	334
		immune evasion in	414

immunotherapy for	415	Classical hormonal negative feedback loop.....	79
prophylactic vaccines for.....	417	Cold ischemia	283
soy in	334	effect on kidney	283
T helper cell immunity in	365	effect on liver	283
vaccine development for.....	415	pancaspase inhibition in	283
Cardiac ischemia	271	Colonoscopic polypectomy	339
models of	271	drug targets in	339
Caspase-1	272	economic aspects of	342
clinical relevance of	273	technical aspects of	341
function of	272	Common g chain (gc) cytoplasmic tail.....	46
in brain ischemia	273	Coreceptors	402
in ischemic injury.....	272	as targets.....	402
in myocardial ischemia	275	Costimulatory molecules.....	402
inhibitors of	272	as targets.....	402
role of genetically altered mice	273	Cytochrome P ₄₅₀ (CYP).....	439
Caspase-1 mutant mice	272	effects of alterations in fluid volume	445
CD4 T helper (Th) cells.....	365	effects of alterations in sympathoadrenal-	
to activate tumor antigen-specific CTL	366	renin system.....	445
Cellular esterases.....	361	effects of ambient levels of glucocorticoids.....	442
in generation of drugs from prodrugs.....	361	effects of calcitropic hormones.....	445
Chemokines	76	effects of cytokines/interleukins/inflammatory	
immunotherapies targeting	76	mediators.....	445
receptors for.....	76	effects of diabetes mellitus	444
with fusion protein and DNA.....	76	effects of growth hormone.....	443
Cholestasis	157	effects of malnutrition/vitamin deficiency.....	445
alterations associated to	157	effects of obesity	444
Cholesterol	133,209	effects of reproductive hormones.....	443
homeostasis of.....	209	effects of thyroid hormone status.....	442
measurement of synthesis of.....	209	endocrine dysregulation	441
transport of.....	133	hormonal effects on.....	439
regulation of metabolism of.....	210	in drug metabolism.....	439
synthesis of.....	209	in osmolality regulation systems/salt	
therapeutic targets/treatment strategies	210	homeostasis.....	445
Cholesterol absorption	209	pharmacogenomics in.....	439
measurement of.....	209	Cytokine signaling.....	87
Cholesterol crystallization.....	177,194	suppressors of.....	87
effects on	194	DC-T-cell interface	401
implications for non-surgical treatment of	177	CD28/B7 pathway.....	403
in bile	177	CD40/CD40L pathway of	403
modulation of.....	177	GITR/GITRL pathway.....	403
Cholesterol gallstone	163	targeting molecules at.....	401
apolipoprotein B (ApoB) in.....	167	Dendritic cells (DCs)	397
apolipoprotein E (ApoE) in	167	alternative activation of.....	407
cholecystokinin A receptor (CCKAR/		CD3 in.....	399
CCK-1R) in	166	in immunological synapse.....	397
cholesteryl ester transfer protein (CETP) in.....	168	pharmacological alteration of	405
cystic fibrosis transmembrane conductance		targeting costimulatory molecules <i>via</i> logical	
regulator (CFTR)/ABC transporter C7 (ABCC7)		alteration of.....	405
in	166	treatments targeting T-cell inter actions with.....	399
family studies of.....	163	Diabetes	51,219323
formation of.....	163	AGE inhibitors in	325
genetic background of.....	163	aminoguanidine in	325
ileal bile salt transporter (SLC10A2).....	166	and cardiac dysfunction.....	220
LDL receptor gene family in.....	167	angiotensin converting enzyme inhibitors in	325
role of human lithogenic genes.....	163	angiotensin II receptor blockers in	325
twin studies of.....	164	animal studies of.....	221
Cholesterol gallstone disease.....	177		

cardiac complications of.....	219	phosphorylation of.....	384
human studies of.....	219	promoter cross-talk.....	384
myocardial insulin action in animal models of.....	222	signaling of.....	305,382
OPB-9195 (hydrazine-derivatives) in.....	325	ubiquitination of.....	385
oxidative stress in.....	323	Estrogen receptor- α /- β /E2.....	305
reduction of hepatic glucose production in.....	51	genomic action mechanisms of.....	305
renoprotection in.....	326	Experimental autoimmune encephalomyelitis (EAE).....	76
therapeutic target in.....	51	TCR-based immunotherapy of.....	75
treatment of.....	51	use of synthetic peptide and DNA vaccines.....	75
Diabetic nephropathy.....	323	Familial intrahepatic cholestasis.....	199
AGE inhibitors in.....	325	Farnesoid X receptor (FXR).....	289
aminoguanidine in.....	325	in human diseases.....	289
angiotensin converting enzyme inhibitors in.....	325	in regulating bile acid homeostasis.....	289
angiotensin II receptor blockers in.....	325	Fatty acid bile acid conjugates (FABACs).....	171
molecular footprints of.....	323	cholesterol metabolism of.....	174
OPB-9195 (hydrazine-derivatives) in.....	325	effects of.....	171
oxidative protein modifications in.....	324	<i>in vitro</i> effects of.....	171
renoprotection in.....	326	<i>in vivo</i> effects of.....	173
role of anti-oxidative.....	324	mechanism of action of.....	174
therapeutic interventions in.....	323	non-biliary effects of.....	174
Dlignodendrocyte progenitor cells (OPCs).....	19	Fatty acid oxidation.....	28
determination of binding constant of.....	61	disorders of.....	28
determination of maximum binding ratio of.....	66	Fatty liver.....	174
determination of stoichiometry of.....	66	Fibrin glue.....	339
DNA-binding drug.....	61	in surgery.....	339
multisite interaction mode of.....	69	Functional foods.....	331
multiple equivalent-site interaction mode of.....	69	clinical applications of.....	331
nonequivalent TOW-site interaction mode of.....	68	effects of.....	331
one to one interaction mode of.....	67	salient features of.....	331
Ductal bile formation.....	139	specific components on health.....	331
cholangiocyte water transport in.....	139	Gallbladder disease.....	143
E2-related cancer.....	308	animal models to.....	144
ideal drugs for.....	309	relevance of water/ion transport.....	143
molecular mechanisms of.....	308	Gallbladder epithelium.....	143
Endocrine disruptors.....	1	ion transport across.....	143
and mRNA polyadenylation.....	3	role of apical anion channels in.....	146
as natural chemicals.....	2	role of apical membrane electrical potential in.....	148
effects of.....	1,5	Gallbladder motility.....	185
in cancer.....	7	drugs affecting.....	185
pharmaceutical applications of.....	2	in fasting (inter digestive).....	186
role in developmental.....	1	medication inhibiting.....	188
role in female reproduction.....	6	medication promoting.....	187
role in male reproduction.....	7	relation to intestinal motility.....	186
target for action of.....	4	Gallbladder.....	144
used in agriculture.....	2	molecular systems promoting ion	
used in industry.....	2	absorptions in.....	144
Estrogens.....	381	molecular systems promoting ion secretion in.....	146
as mitogens.....	381	role of apical anion channels in.....	146
in estrogen signaling.....	383	role of apical membrane electrical potential in.....	148
metabolites of.....	381	Gallstone.....	171,185,204
signaling of.....	381	bile secretion in.....	205
Estrogen receptors.....	305,381	medication for non-surgical treatment of.....	188
acetylation of.....	385	non-surgical treatment of.....	171
cross talk with growth factors.....	384		
DNA-dependent/ERE-independent signaling of.....	382		
ERE-dependent signaling of.....	382		
glycosylation of.....	385		
heterodimerization of.....	383		

prevention of	185	HOLA-class II epitopes	367
treatment of	185	methods of identifying	367
Gene therapy	199	Homeostasis	295
manipulation of biliary lipids by	199	6-ECDCA as ligand for	299
progress in	199	fexaramine as ligand for	299
Glutamate	360	FXR in	295
Glutathione S-conjugates	155	FXR molecular mechanism of	295
fate of	155	gene regulation of	296
formation of	155	GW4064 as ligand for	299
Glycolipid ligands	315	LXR α in	295
for natural killer (NK) T cells	315	role in hepatic function	296
role in suppression of autoimmune diseases	315	SHP-dependent mechanism of	296
therapeutic potential of	315	SHP-independent mechanism of	296
Glycolipid therapies	317	synthetic ligand of	298
for autoimmune diabetes in NOD mice	319	target genes of	296
for autoimmune disease models	317	Hormonal contraception	249
for autoimmune diseases	320	acceptability of	254
for collagen-induced arthritis	319	buccal route of	252
for experimental autoimmune		effectiveness of	254
encephalomyelitis	317	in men	249
for mouse models of systemic lupus		long-acting combination regimes of	253
erythematosus	319	oral administration of	251
GP130 cytokines/receptors	262	self-administered combination regimes of	251
action on anterior pituitary	262	synthetic androgen preparations for	254
expression of	262	Human gallstone genes	164
in pituitary cell growth	262	ABC transporter B4 as	164
in regulation of hormone secretion	262	as drug targets	164
GP130/IL-6 cytokine family	260	cholesterol 7 α -hydroxylase (CYP7A1) of	166
Growth hormone (GH)	79	IL-2/15R β cytoplasmic tail	45
diabetogenic effects of	80	IL-2R α chain	45
growth-promoting effects of	79	IL-2R structure	44
insulin-like effects of	79	Immune homeostasis	413
metabolic effects of	80	failure of	413
pleiotropic effects of	79	transfection with cytokines/co-stimulation in	416
role of Janus kinase 2	81	Immunosuppression	397
signal transduction of	81	altered peptide ligands in	402
signaling mechanism for	79	anti-CD4/CD8 antibodies in	402
Helper T cell	365	CD45 in	404
to activate tumor antigen-specific B cells	367	CD47 in	404
to activate tumoricidal cells of innate immune		ILT3 in	404
effector arm	366	ILT4 in	404
to kill tumor cells	367	intervention at dendritic cell-T-cell interface in	397
Hepatic glucose flux	51	LFA-1/ICAM-1	404
and glucose homeostasis	51	PD-1 in	404
Hepatic glucose production	52	stimulating inhibitory receptors in	403
dysregulation of	52	targeting cytokine secretion in	405
enzymatic regulation of	52	upregulation of inhibitory receptors in	407
strategies/approaches for	55	Immunotherapy	73
therapeutic targets for reduction of	55	against organ-specific autoimmune disease	73
Hepatobiliary aquaporins	141	new approach to	73
pathophysiologic significance of	141	Inflammatory factors	16
HLA-class II peptides	367	neuroprotective effects of	16
biochemical/bioinformatics techniques for	368	Innate immune effectors	241
characteristics of	367	angiogenins as	242
HLA-class II-expressing tumors	365	cathelicidins as	241
		defensins as	241

lactoferrin as	242	Mitochondrial trifunctional protein (MTP)	27
lysozyme as	242	disorders of	28
phospholipases as	242	mouse model for	27
Innate immune system	237	Mitochondrial trifunctional protein defects	27
complement system in	240	and maternal liver disease	31
pathogen detection by	238	and TAT-MTS fusion proteins	36
signaling through TLRs	239	current management of	32
targets for drug development	237	genotypes in	31
Insulin receptor	83	molecular basis of	27,30
and phosphatidyl inositol-3 kinase	83	MTP β -subunit defects as	31
substrates for	83	mutations in	30
Insulin regulation	426	non-viral gene therapy for	33
repression vs. interference	426	novel therapeutic approaches for	27
Ischemic organ injury	269	phenotypes in	31
animal models of	270	potential therapies for	33
drug targets in	269	protein transduction domains for	34
pancaspase inhibitors in	278	role of TAT-MTS fusion proteins	35
pro-apoptotic caspases in	278	viral gene therapies for	33
role of caspases	269	Modified hepatocytes	199
Ischemic tissue injury	269	liver repopulation by	199
animal models of	270	Multiple sclerosis	11,74,417
apoptosis in	269	and other human diseases	74
inflammation in	270	autoimmunity in	417
necrosis in	269	axonal pathology in animal models of	12
pancaspase inhibitors in	278	challenges in the prevention of	11
pro-apoptotic caspases in	278	chemokine profiles in	75
Kidney	149	cytokine in	75
intestine	146	exitotoxicity in	17
Leptin	203	glutamate in	17
biological aspects of	203	immune system in	419
in human gallstones disease	206	immunotherapy for	419
Lipids	131,193	molecular activation of endogenous progenitors in	20
pharmacological manipulation of	193,196	prospect for exogenous progenitors in	21
transport into bile	131	regeneration in	11
Lipoid congenital adrenal hyperplasia (lipoid CAH)	101	relationship of inflammation with	13
mouse star knockout models of	101	response of progenitors to inflammatory	
pathogenesis of	101	environment in	20
physio-pathological consequences in	101	role of nitric oxide	16
Liver damage	200	role of sodium and calcium channels	17
hepatocyte transplantation in models with	200	strategies to improve self regulation in	418
Liver disease	373	targeting cell migration into CNS for	418
anti-HAV-HBV vaccinations	374	TCR-based immunotherapy of	75
antiviral therapy for	375	use of synthetic peptide and DNA vaccines	75
blood donors screening for	374	Myocardial insulin resistance	219
diagnostic tests for	374	and cardiac dysfunction	220
drug targets for	373	animal studies of	221
liver/bone marrow transplantation	376	human studies of	219
management of	in374	myocardial insulin action in animal models of	222
primary prevention of	374	studies in transgenic mice with altered	
secondary prevention of	374	myocardial insulin action for	223
treatment for	375	Myocardial ischemia	280
Liver repopulation	200	pancaspase inhibitors in	280
progressive familial intrahepatic cholestasis	200	pro-apoptotic caspases in	280
		Natural killer T (NKT) cells	315
		antigens of	315
		in human autoimmune diseases	320
		in multiple sclerosis	320
		in systemic autoimmune disease	320

- in type 1 diabetes 320
 regulation of cytokine production by 316
 Neural regeneration 17
 in MS 17
 Neural stem 19
 Neurodegeneration 11
 relationship of inflammation with 13
 role of nitric oxide 16
 role of sodium and calcium channels 17
 role of T cells 15
 therapeutic strategies to prevent 11
 Neuronal/axonal degeneration 11
 challenges in the prevention of 11
 Neurotoxic 15
 inflammatory mediators as 15
 NF κ B 350
 acts as molecular switch of inflammatory
 arthritis/osteoclastogenesis 350
 Nuclear receptors 291
 function of 292
 in cholesterol/bile acids homeostasis 293
 responsive element of 291
 structure of 291
 superfamily of 291
 Obesity 203,219
 cardiac phenotypes in 219
 gallstone formation/therapy in 203
 Organ-specific autoimmune disease 73
 animal models of 74
 characterization of pathogenic T cell receptor
 (TCR) in 74
 other animal models for 74
 role of cell receptor 73
 TCR-based immunotherapy of 75
 use of chemokine receptor DNA vaccines 73
 use of synthetic peptide and DNA vaccines 75
 Osteoclast 347
 advances in 347
 cellular molecular regulation of activity of 350
 differentiation of 347
 function of 347
 in apoptosis 352
 regulation of differentiation of 349
 signal transduction pathways in 348
 survival of 352
 Phosphoenolpyruvate carboxykinase (PEPCK) 423
 developmental regulation of 424
 Phosphoenolpyruvate carboxykinase (PEPCK) gene
 expression 423
 animal/cell models for 425
 chromatin state of 424
 insulin regulation of 423
 putative regulators of 430
 role of glucocorticoid response 429
 role of co-activators of cAMP response 429
 targets for 431
 transcription regulation of 425
 Phosphoenolpyruvate carboxykinase (PEPCK) promoter
 426
 effect of glucagons/cAMP/PKA response 427
 role of CREB/C/EBP 428
 Phospholipids 181
 Plasma cholesterol-lowering drugs 209
 efficacy of 209
 modes of action of 209
 Plasma membrane receptor 307
 Postprandial gallbladder motility 186
 Prodrugs 360
 as esters of a-carboxyl group of neutral
 amino acid 361
 as esters of side chain carboxyl group 360
 as esters of side chain hydroxyl group in
 amino acids serine/threonine 361
 Progenitor cells 19
 Progressive familial intrahepatic cholestasis 200
 caused by defect in biliary lipid secretion 201
 Progressive familial intrahepatic cholestasis type 1 200
 Progressive familial intrahepatic cholestasis type 2 201
 Prolactin (PRL) secretory cells 260
 R3-binding chemokines 109
 as novel multifunctional therapeutic target 109
 chromosome localization of 110
 in autoimmune thyroid disorders 115
 in cancer biology 111
 in diabetes 113
 in engraftment in allograft survival 112
 in multiple sclerosis 114
 in proliferative glomerulonephritis 133
 pleiotropic biologic functions of 109
 receptors of 110
 Real-time DNA-drug interaction kinetics 64
 principle of 64
 Renal ischemia 271
 models of 271
 pancaspase inhibitors in 282
 pro-apoptotic caspases in 282
 Respiratory syncytial virus 419
 cytokine induction in 419
 immunopathology induced by infection with 419
 infection of 419
 role of antibodies in 420
 vaccines for 420
 Rheumatoid arthritis (RA) 41
 activation of P1-3K pathway in 46
 anticytokine therapy for 41,48
 blockade of IL-2R by specific antibodies in 48
 CsA mechanism of action in 47

destructive effects of.....	41	non-functional protein of.....	101
immunosuppressive agents in.....	46	pathways involved in expression of.....	99
role of IL-2/IL-2R.....	43	post-translational modification of.....	99
role of interleukin 15(IL-15).....	46	regulation of.....	93
signal transduction by IL-2 in.....	41	role MAPK-ERKs cascade.....	100
signal transduction <i>via</i> JAK-STAT pathway in.....	46	role of arachidonic acid.....	100
signaling <i>via</i> MAPK pathway in.....	45	role of calcium messenger systems.....	99
target in.....	41	role of chloride ions.....	100
treatment of.....	41	role of transcription factors in.....	96
		tissue-specific regulation of.....	95
Signal transducers and activators of transcription		Surface plasmon resonance biosensor technology.....	61
(STAT).....	85,449	multiple equivalent-site interaction mode of.....	69
application of.....	467	multisite interaction mode of.....	69
as regulator of immune/cancer cells.....	449	nonequivalent TOW-site interaction mode of.....	68
as solid tumors.....	455	one to one interaction mode of.....	67
biological activity of.....	449,466	target DNA by.....	61
conventional/novel inhibition strategies for.....	456	T helper cell vaccines.....	369
in acute lymphocytic leukemia (ALL).....	454	clinical translation of.....	369
in acute myelogenous leukemia (AML).....	453	TCR/MHC interaction.....	401
in autoimmune diabetes.....	467	as target.....	401
in chronic myelogenous leukemia (CML).....	454	Testosterone.....	250
in chronic myelomonocytic leukemia		buccal route of.....	252
(CMML).....	454	regimes of.....	250
in experimental allergic encephalomyelitis		secretion of.....	250
(EAE).....	469	self-administered combination regimes of.....	251
in head and neck cancer.....	456	<i>via</i> transdermal route.....	252
in human cancer cells.....	452	TGF- β superfamily.....	263
in human leukemia virus type 1(HTLV-1)		action on pituitary cells.....	264
infected cells.....	455	and SMADS proteins.....	263
in inflammatory bowel disease (IBD).....	471	expression of.....	264
in inflammatory diseases.....	456	in pituitary cell growth.....	264
in leukemias.....	453	in regulation of hormone secretion.....	264
in multiple sclerosis (MS).....	469	receptors of.....	264
in myeloproliferative syndrome (EMS).....	455	Thalassemia.....	373
in organ transplantation.....	472	chelation therapy for.....	375
in ovarian and uterine cancers.....	456	drug targets for.....	373
in prostate cancer.....	456	liver/bone marrow transplantation in.....	376
in rheumatoid arthritis (RA).....	470	management of liver disease in.....	373
in sepsis/endotoxin induced shock.....	471	Tranplantation.....	201
in systemic lupus erythematosus (SLE).....	470	of hepatocytes in murine model of PFIC type 3.....	201
interleukin-10 (IL-10).....	465	Tumor.....	414
production of.....	465	adjuvants in.....	416
regulation of signaling functions of.....	451	antigen in.....	416
role in relationship between health/disease.....	466	autoimmunity in.....	417
structure of.....	449	combination immunotherapy for.....	417
therapeutic effects/mechanisms of.....	465	dendritic cell immunotherapy for.....	416
up-regulatory agents of.....	467	geriatric immunity in.....	416
up-regulatory drugs on diseases.....	467	immune evasion in.....	414
Spermatogenesis.....	249	induced immunosuppression.....	414
regulation of.....	249	transfection with cytokines/co-stimulation in.....	416
Stable isotopes.....	212	Tumor antigen-specific Th cells.....	365
absorption.....	213	Tumoral neuroendocrine pituitary cells.....	259
experimental approaches.....	212	signaling processes in.....	259
Star expression.....	94	targets for therapeutic drugs.....	259
regulation of.....	94	Type 1 diabetes mellitus.....	227
Sterdogenic acute regulatory (StAR) protein.....	93	anti-CD3 antibody in.....	232
autoregulation of.....	96		
development of.....	95		
functional/physiological consequences for.....	93		
hormonal regulation of.....	95		

cyclosporin in.....	231	Ursodeoxycholate.....	181
DiaPep277 in.....	233		
glutamic acid decarboxylase in.....	234		
intervention in new-onset of.....	231	Wallerian degeneration.....	13
nicotinamide for.....	228	relationship of inflammation with.....	13
pathogenesis of.....	227	Water transport.....	137
prevention of.....	227,228	into bile.....	137
role of cow's mild antigen.....	231	role in bile formation.....	137
role of insulin.....	228		
therapeutic targets for.....	227		